CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

Pigs Modified With CRISPR Gene-Editing Technology Could Be Available For Human Consumption Very Soon TwistedSifter Battery ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

Algen Biotechnologies said on Monday it had agreed to grant AstraZeneca a license to develop therapies the U.S.-based biotech ...

This makes the organs virus-free and less likely to trigger an immune response, improving their safety and durability.

AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial ...

The company is gene editing crops to make our food supply more resilient to climate change.

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

Turning genes on and off is like flipping a light switch, controlling whether genes in a cell are active. When a gene is turned on, the production of proteins or other substances is promoted; when ...

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.